Hypofractionated proton therapy for benign tumors of the central nervous system: A systematic review of the literature.

Aim of the present analysis was to report results of a systematic review of the literature in the setting of patients treated with hypoF PT for benign lesions of the central nervous system (CNS). The methodology complied with the PRISMA recommendations. PubMed, EMBASE and Scopus databases were interrogated in September 2022. Twelve papers have been selected including patients treated for base of the skull meningiomas (6 papers), vestibular schwannoma (3 papers) and pituitary adenomas (3 papers). Clinical outcomes were evaluated with both radiologic images and clinical parameters. Long-term toxicity was reported in all but one series with an incidence ranging from 2 % to 7 % in patients treated for base of skull meningioma and 1–9 % for schwannoma. HypoF PT is a safe and effective treatment in selected benign tumors of the CNS. Further dosimetric and clinical comparisons are required to better refine the patients' selection criteria. • Clinical data on hypofractionated Proton Therapy are rapidly increasing. • QoL is of particular importance for benign tumor of the CNS. • Hypofractionated PT confirmed to an effective alternative to the photon approach. [ABSTRACT FROM AUTHOR]